Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:ERAS

Erasca Q2 2025 Earnings Results & Report

Erasca logo
$14.73 +0.03 (+0.22%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Erasca met analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.12 versus the -$0.12 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Erasca EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.12
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Erasca Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Erasca's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Erasca's Q2 2025 Press ReleasePress Release
(8-K)
Erasca's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Erasca Q2 2025 Earnings FAQ

Erasca (NASDAQ:ERAS) reported earnings of -$0.12 per share for Q2 2025, matching the consensus estimate of -$0.12. The report was announced on Tuesday, August 12, 2025.

Erasca's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Erasca on the company's earnings history page.

Erasca Earnings Headlines

Erasca (NASDAQ:ERAS) Shares Down 5.1% - What's Next?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088094
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951989-erasca-revolutions-approval-just-took-risk-out-of-the-fast-follower
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 15 at 1:00 AM  |  Chaikin Analytics (Ad)
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366747/0/en/erasca-inc-nasdaq-eras-shareholder-investigation-alert-bernstein-liebhard-investigates-potential-breaches-of-fiduciary-duty.html
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
September 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/21/3365561/0/en/long-term-shareholders-of-erasca-inc-eras-are-encouraged-to-contact-johnson-fistel-regarding-potential-claims.html
Erasca’s ERAS-601 Trial Completion: What Early Cancer Data Could Mean for Investors
September 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/erascas-eras-601-trial-completion-what-early-cancer-data-could-mean-for-investors?utm_source=marketbeat.com&utm_medium=referral
See More Erasca Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email.

About Erasca

Erasca (NASDAQ:ERAS) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers driven by abnormal signaling in the RAS/MAPK pathway. The company’s research and development activities target tumors with RAS mutations or other alterations that can promote cancer growth and resistance to treatment.

Erasca’s pipeline has included naporafenib, an investigational pan-RAF inhibitor designed to block signaling downstream of RAF proteins, as well as other targeted therapies aimed at genetically defined cancer populations. Its programs are being evaluated in clinical studies, including potential treatments for solid tumors with limited therapeutic options.

Founded in 2018 and headquartered in San Diego, California, Erasca became a publicly traded company on the Nasdaq under the symbol ERAS in 2021. The company is led by co-founder and Chief Executive Officer Jonathan E. Lim, M.D. Its operations are primarily focused on oncology research and clinical development in the United States, with collaborations and trial activities potentially extending to other regions.

View Erasca Profile
Earnings Tools